View Item 

Show simple item record

Progression of esophageal dysplasia to cancer
dc.contributor.authorAppelman, Henry D.en_US
dc.contributor.authorMatejcic, Marcoen_US
dc.contributor.authorParker, M. Iqbalen_US
dc.contributor.authorRiddell, Robert H.en_US
dc.contributor.authorSalemme, Mariannaen_US
dc.contributor.authorSwanson, Paul E.en_US
dc.contributor.authorVillanacci, Vincenzoen_US
dc.date.accessioned2014-10-07T16:09:29Z
dc.date.availableWITHHELD_12_MONTHSen_US
dc.date.available2014-10-07T16:09:29Z
dc.date.issued2014-09en_US
dc.identifier.citationAppelman, Henry D.; Matejcic, Marco; Parker, M. Iqbal; Riddell, Robert H.; Salemme, Marianna; Swanson, Paul E.; Villanacci, Vincenzo (2014). "Progression of esophageal dysplasia to cancer." Annals of the New York Academy of Sciences 1325(1): 96-107.en_US
dc.identifier.issn0077-8923en_US
dc.identifier.issn1749-6632en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/108637
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherIARCen_US
dc.subject.otherBarrett's Esophagusen_US
dc.subject.otherEsophageal Adenocarcinomaen_US
dc.subject.otherP52en_US
dc.subject.otherRacemaseen_US
dc.subject.otherLectinen_US
dc.subject.otherOESOen_US
dc.titleProgression of esophageal dysplasia to canceren_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelScience (General)en_US
dc.subject.hlbtoplevelScienceen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/108637/1/nyas12523.pdf
dc.identifier.doi10.1111/nyas.12523en_US
dc.identifier.sourceAnnals of the New York Academy of Sciencesen_US
dc.identifier.citedreferenceFitzgerald, R.C., M. di Pietro, K. Ragunath, et al. 2014. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 63 ( 1 ): 7 – 42. doi: 10.1136/gutjnl‐2013‐305372. Epub 2013 Oct 28.en_US
dc.identifier.citedreferenceLanuti, M., G. Liu, J.M. Goodwin, et al. 2008. A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin. Cancer Res. 14: 3216.en_US
dc.identifier.citedreferenceMurray, L. & Y. Romero. 2009. Role of obesity in Barrett's esophagus and cancer. Surg. Oncol. Clin. N. Am. 18: 439 – 452.en_US
dc.identifier.citedreferenceIijima, K., J. Grant, K. McElroy, et al. 2003. Novel mechanism of nitrosative stress from dietary nitrate with relevance to gastro‐oesophageal junction cancers. Carcinogenesis. 24: 1951.en_US
dc.identifier.citedreferenceRichter, J.E., G.W. Falk & M.F. Vaezi. 1998. Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad. Am. J. Gastroenterol. 98: 1800 – 1802.en_US
dc.identifier.citedreferenceZhai, R., F. Chen, G. Liu, et al. 2010. Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J. Clin. Oncol. 28: 2445.en_US
dc.identifier.citedreferenceSharma, P., G.W. Falk, A.P. Weston, et al. 2006. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin. Gastroenterol. Hepatol. 4: 566 – 572.en_US
dc.identifier.citedreferenceBian, Y.S., M.C. Osterheld, F.T. Bosman, et al. 2001. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod. Pathol. 14: 397 – 403.en_US
dc.identifier.citedreferenceKaye, P.V., S.A. Haider, M. Ilyas, et al. 2009. Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistocheimisty. Histopathology 54: 699 – 712.en_US
dc.identifier.citedreferenceSkacel, M., R.E. Petras, L.A. Rybicki, et al. 2002. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. Am. J. Gastroenterol. 97: 2508 – 2513.en_US
dc.identifier.citedreferenceKastelein, F., K. Biermann, E.W. Steyerberg, et al. 2013. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut. 62: 1676 – 1683.en_US
dc.identifier.citedreferenceMechref, Y., A. Hussein, S. Bekesova, et al. 2009. Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets. J. Proteome Res. 8: 2656 – 2666.en_US
dc.identifier.citedreferenceMann, B., M. Madera, I. Klouckova, et al. 2010. A quantitative investigation of fucosylated serum glycoproteins with application to esophageal adenocarcinoma. Electrophoresis. 31: 1833 – 1841.en_US
dc.identifier.citedreferenceBird‐Lieberman, E.L., J.M. Dunn, H.G. Coleman, et al. 2012. Population‐based study reveals new risk‐stratification biomarker panel for Barrett's esophagus. Gastroenterology 143: 927 – 935.en_US
dc.identifier.citedreferenceTateno, H., S. Nakamura‐Tsuruta & J. Hirabayashi. 2009. Comparative analysis of core‐fucose‐binding lectins from Lens culinaris and Pisum sativum using frontal affinity chromatography. Glycobiology 19: 527 – 536.en_US
dc.identifier.citedreferenceBrooks, S.A. 2000. The involvement of Helix pomatia lectin (HPA) binding N‐acetylgalactosamine glycans in cancer progression. Histol Histopathol. 15: 143 – 158.en_US
dc.identifier.citedreferenceYoshida, Y., T. Okamura & T. Shirakusa. 1993. An immunohistochemical study of Helix pomatia agglutinin binding on carcinoma of the esophagus. Surg. Gynecol. Obstet. 177: 299 – 302.en_US
dc.identifier.citedreferenceBird‐Lieberman, E.L., A.A. Neves, P. Lao‐Sirieix, et al. 2012. Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. Nat. Med. 18: 315 – 321.en_US
dc.identifier.citedreferenceBertani, H., M. Frazzoni, E. DAbizzi, et al. 2013. Improved detection of incident dysplasia by probe‐based confocal laser endomicroscopy in a Barrett's esophagus surveillance program. Dig. Dis. Sci. 58: 188 – 193.en_US
dc.identifier.citedreferenceDunbar, K.B., 2011. Endomicroscopy in the evaluation of Barrett's esophagus. Curr. Opin. Gastroenterol. 27: 374 – 382.en_US
dc.identifier.citedreferenceDorer, R. & R.D. Odze. 2006. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Am. J. Surg. Pathol. 30 ( 7 ): 871 – 877en_US
dc.identifier.citedreferencevan Schaik, F.D., B. Oldenburg, G. Offerhaus. et al. 2012. Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis. Inflamm. Bowel Dis. 18 ( 3 ): 480 – 488.en_US
dc.identifier.citedreferenceLisovsky, M., O. Falkowski & T. Bhuiya. 2006. Expression of alpha‐methylacyl‐coenzyme A racemase in dysplastic Barrett's epithelium. Hum Pathol. 37 ( 12 ): 1601 – 1606.en_US
dc.identifier.citedreferenceSträter, J., C. Wiesmüller & S. Perner, 2008. Alpha‐methylacyl‐CoA racemase (AMACR) immunohistochemistry in Barrett's and colorectal mucosa: only significant overexpression favours a diagnosis of intraepithelial neoplasia. Histopathology. 52 ( 3 ): 399 – 402.en_US
dc.identifier.citedreferenceScheil‐Bertram, S., D. Lorenz & C. Ell, 2008. Expression of alpha‐methylacyl coenzyme A racemase in the dysplasia carcinoma sequence associated with Barrett's esophagus. Mod. Pathol. 21 ( 8 ): 961 – 967.en_US
dc.identifier.citedreferenceSonwalkar, S.A., O. Rotimi, N. Scott, et al. 2010. A study of indefinite for dysplasia in Barrett's oesophagus: reproducibility of diagnosis, clinical outcomes and predicting progression with AMACR (alpha‐methylacyl‐CoA‐racemase). Histopathology. 56 ( 7 ): 900 – 907.en_US
dc.identifier.citedreferenceKastelein, F., K. Biermann, E.W. Steyerberg, et al. 2013. ProBar study group. Value of α‐methylacyl‐CoA racemase immunochemistry for predicting neoplastic progression in Barrett's oesophagus. Histopathology. 63 ( 5 ): 630 – 639.en_US
dc.identifier.citedreferenceShimizu, M., G. Zaninotto, K. Nagata, et al. 2013. Esophageal squamous cell carcinoma with special reference to its early stage. Best Pract. Res. Clin. Gastroenterol. 27 ( 2 ): 171 – 186.en_US
dc.identifier.citedreferenceMontgomery, E., J.K. Field, P. Boffetta, et al. 2010. Squamous cell carcinoma of the oesophagus. In WHO Classification of Tumours of the Digestive System. F.T. Bosman, F. Carneiro, R.H. Hruba, N.D. Theise, Eds.: 18 – 24. Lyon: IARC.en_US
dc.identifier.citedreferenceOdze, R.D., J.R. Goldblum & J.M. Crawford. 2004. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas Eds.: 381 – 408. Philadelphia: Saunders.en_US
dc.identifier.citedreferenceFenoglio‐Preiser, C.M., A.E. Noffsinger, G.N. Stemmermann, et al. 2008. Gastrointestinal pathology. In An Atlas and Text. 3rd Ed.: 86 – 109. Philadelphia: Lippincott Williams & Wilkins.en_US
dc.identifier.citedreferenceDawsey, S.M., K.J. Lewin, G.Q. Wang, et al. 1994. Squamous esophageal histology and subsequent risk of squamous cell carcinoma of the esophagus. A prospective follow‐up study from Linxian, China. Cancer. 74 ( 6 ): 1686 – 1692.en_US
dc.identifier.citedreferenceWang, G.Q., C.C. Abnet, Q. Shen, et al. 2005. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut. 54 ( 2 ): 187 – 192.en_US
dc.identifier.citedreferenceMandard, A.M., P. Hainaut & M. Hollstein. 2000. Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat. Res. 462 ( 2–3 ): 335 – 342.en_US
dc.identifier.citedreferenceLiu, M., F. Zhang, S. Liu, et al. 2011. Loss of heterozygosity analysis of microsatellites on multiple chromosome regions in dysplasia and squamous cell carcinoma of the esophagus. Exp. Ther. Med. 2 ( 5 ): 997 – 1001.en_US
dc.identifier.citedreferenceChen, J., D.L. Kwong, T. Cao, et al. 2013. Esophageal squamous cell carcinoma (ESCC): advance in genomics and molecular genetics. Dis Esophagus doi: 10.1111/dote.12088.en_US
dc.identifier.citedreferenceGuo, M., J. Ren, M.G. House, et al. 2006. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin Cancer Res. 12 ( 15 ): 4515 – 4522.en_US
dc.identifier.citedreferenceRiddell, R.H., H. Goldman, D.F. Ransohoff, et al. 1983. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 14 ( 11 ): 931 – 968.en_US
dc.identifier.citedreferenceLevine, D.S., P.L. Blount, R.E. Rudolph & B.J. Reid. 2000. Safety of a systematic endoscopic biopsy protocol in patients with Barrett's esophagus. Am J Gastroenterol. 95 ( 5 ): 1152 – 1157en_US
dc.identifier.citedreferenceReid, B.J., P.L. Blount, Z. Feng & D.S. Levine. 2000. Optimizing endoscopic biopsy detection of early cancers in Barrett's high‐grade dysplasia. Am. J. Gastroenterol. 95 ( 11 ): 3089 – 3096.en_US
dc.identifier.citedreferenceReid, B.J., R.C. Haggitt, C.E. Rubin, et al. 1988. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum. Pathol. 19 ( 2 ): 166 – 178.en_US
dc.identifier.citedreferenceCurvers, W.L., F.J. ten Kate, K.K. Krishnadath, et al. 2010. Low‐grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am. J. Gastroenterol. 105 ( 7 ): 1523 – 1530.en_US
dc.identifier.citedreferenceIreland, A.P., G.W. Clark & T.R. DeMeester. 1997. Barrett's esophagus. The significance of p53 in clinical practice. Ann. Surg. 225 ( 1 ): 17 – 30.en_US
dc.identifier.citedreferenceEdgren, G., H.O. Adami, E. Weiderpass & O. Nyrén. 2013. A global assessment of the oesophageal adenocarcinoma epidemic. Gut. 62: 1406.en_US
dc.identifier.citedreferenceHvid‐Jensen, F., L. Pedersen, A.M. Drewes, et al. 2011. Incidence of adenocarcinoma among patients with Barrett's esophagus. N. Engl. J. Med. 365: 1375.en_US
dc.identifier.citedreferenceWani, S. & P. Sharma. 2006. Barrett's adenocarcinoma. GI Motility online doi: 10.1038/gimo45.en_US
dc.identifier.citedreferenceKuwano, H., H. Kato, T. Miyazaki, et al. 2005. Genetic alterations in esophageal cancer. Surg. Today. 35: 7 – 18.en_US
dc.identifier.citedreferenceMaley, C.C., P.C. Galipeau, J.C. Finley, et al. 2006. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 38: 468 – 473.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
nyas12523.pdf
Size:
1.033MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.